Drug profile · INN
levofloxacin
QUINSAIR
levofloxacin (QUINSAIR) is a dna gyrase inhibitor. Associated with Teva Pharma GmbH. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — levofloxacin
- US status
- approved
- Class
- Antiinfectives for systemic use (J01)
- Route
- OPHTHALMIC
- Patents
- 1
- Programs
- 9
- Data quality
- 0.89
Quick answer
levofloxacin (QUINSAIR) is a dna gyrase inhibitor. Associated with Teva Pharma GmbH. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
DNA gyrase inhibitor
Primary target: DNA gyrase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is levofloxacin?
levofloxacin (QUINSAIR) is a dna gyrase inhibitor. Associated with Teva Pharma GmbH. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for levofloxacin?
QUINSAIR is a marketed brand name for levofloxacin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of levofloxacin?
levofloxacin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.